4SCAR-PSMA T cells
Preclinical
4SCAR-PSMA T cells is one of 10 therapeutic programs targeting Tumors. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
11 competitors in Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 2
Proleukin
IIovance Biotherapeutics, Inc.
Phase 2
Tazverik
EEpizyme, Inc.
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Lynparza
AstraZenecaPreclinical
Lu-177-DOTATATE
NNational Cancer Institute (NCI)
Preclinical
4SCAR-PSMA T cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for 4SCAR-PSMA T cells. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]